Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib

Review

(2430) Views  (738) Full article downloads

Authors: Richard Quek, Suzanne George

Published Date February 2010 Volume 2010:4 Pages 19 - 31

DOI: http://dx.doi.org/10.2147/BTT.S4396

Richard Quek¹, Suzanne George²

¹Visiting Fellow, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; ²Clinical Director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Abstract: In the last decade a tremendous amount has been learned about the biology and treatment of gastrointestinal stromal tumor (GIST). Imatinib mesylate has revolutionized the treatment of metastatic GIST. In addition, the role of imatinib in localized GIST has gained much interest and may improve patient outcomes. Additionally, research efforts aimed at understanding the biology and the molecular heterogeneity of GIST both at initial presentation and at the time of resistance to imatinib, has helped guide rational approaches to treatment as well as future efforts aimed at treating imatinib-resistant GIST.

Keywords: gastrointestinal stromal tumors, GIST, review, imatinib, tyrosine kinase inhibitor, TKI